So we got a little takeover Tuesday but not the mega deals that would have been transformative. I think we are at the point that we likely needed a deal after the long weekend to keep the momentum going. This is not to say we need deals every week but I suspect it would have […]
May 26 Biotech Update
Yesterday was more of the same and that is actually good for one of the first times this year. The sector continues higher and modestly outperformer the broader markets. The one negative was that ISI noted that there has been a lack of real money interest. In other words, long term institutional money has not […]
13F Analysis of Best Performing Healthcare Hedge Funds (Q1 2015)
13F filings have arrived and it’s like Christmas day for me. I’ve been pouring through the filings, tweeting the interesting ones, and probably annoying everyone on twitter. These filings are a great idea generation tool, a starting place for due diligence, and way to get a peek at the focus of the best minds in […]
March 25 Biotech Update
A rough start to morning for the sector with a biotech bubble article in the WSJ not helping. There was nothing new but the headline is the headline (it also had some odd numbers like CELG P/E over 50, which is much higher than the numbers I usually see when calculating CELG P/E). Of course, […]
March 10 Biotech Update
The pullback continues. It seems like the downdraft may be extended in the near term setting up a bounce but I am not convinced it would be more than simply a bounce as part of a larger correction. I still worry about the underperformance of the large caps in that it is the SMID that […]
Chimera Research Group Catalyst Summary for January 2015
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. JANUARY 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that their Phase 3 CheckMate-017 trial evaluating Opdivo versus docetaxel for the treatment of refractory squamous cell non-small cell lung cancer […]
A look at Auspex Pharma
Lately, it seems like there is a new biotech IPO being filed every other day. Today, we want to take a look at a recent IPO, Auspex Pharmaceuticals (ASPX). Auspex recently raised 7 million shares at $12 per share and has roughly 22.5 million shares outstanding. It is currently valued around $550 million in market […]
Quick Take On NBIX
I have not followed this story before today, but I’ll throw my hat into the ring anyways It looks like Phase 2b results turned out positive in this second study due to some key differences. The first being a dose titration, lower average AIM score, and central raters. I think this bodes well for eventual […]
Week’s Option Activity (8/19~8/22)
The following stocks had notable activity in their options during the past week: $AMRN (8/19): 5,000 OCT 7.0 strike Calls (stock at $6.00) were sold for 0.87 or $435,000 total proceeds. Seller makes money as long as stock trades below $7.87 by expiration. This trade may also be a current long stockholder selling Calls to […]
